Rationale for Left Ventricular Support During Percutaneous Coronary Intervention

Similar documents
Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Recovering Hearts. Saving Lives.

Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California

Management of Acute Shock and Right Ventricular Failure

Introduction to Acute Mechanical Circulatory Support

Circulatory Support: From IABP to LVAD

TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4

The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities

Case - Advanced HF and Shock (INTERMACS 1)

Bridging With Percutaneous Devices: Tandem Heart and Impella

Acute Myocardial Infarction Complicated by Cardiogenic Shock

Impella Ins & Outs. CarVasz November :45 12:15

Assist Devices in STEMI- Intra-aortic Balloon Pump

Mechanics of Cath Lab Support Devices

Ted Feldman, M.D., MSCAI FACC FESC

Who is the high risk patient?

Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital

Mechanics of Cath Lab Support Devices

Antonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017

Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support

Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

Guideline compliance, utilization trends

What do the guidelines say?

ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research

Percutaneous Mechanical Circulatory Support Devices

Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017

Mitigating Operator Risk in Complex Interventional Procedures. Tanveer Rab, MD, FACC Ajay Kirtane, MD, FACC Prashant Kaul, MD, FACC

Acute Mechanical Circulatory Support Right Ventricular Support Devices

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands

presenters 2010 Sameh Sabet Ain Shams University

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

Management of Cardiogenic shock. Prof. Christian JM Vrints

Cardiogenic Shock. Carlos Cafri,, MD

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

The majority of patients with cardiomyopathy

CLINICAL DOSSIER Protected PCI

Management of High-Risk Coronary Artery Disease

Ventricular Assisting Devices in the Cathlab. Unrestricted

Left Main Intervention: Will it become standard of care?

The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize

LM stenting - Cypher

Cardiogenic Shock in Acute MI

High Risk PCI for Heart Failure

How to do Primary Angioplasty. - Patients with Cardiogenic Shock

Surgery Grand Rounds

Emergency surgery in acute coronary syndrome

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST

Acute Circulatory Support Should We or Shouldn t We?

Unprotected LM intervention

Ischemic Heart Disease Interventional Treatment

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Rhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale

Ischemic Heart Disease Interventional Treatment

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

Clinical Considerations for CTO

The number of patients in the United States with

Lessons learned From The National PCI Registry

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy

headline a Protected PCI Program: Treating the Most Complex Patients

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

The Robert TV Kung Interventional Heart Failure Fellowship Program Bringing Hope to the Hopeless at Tufts

Andrew Civitello MD, FACC

Long-Term Management: Preventing Progression. Daniel Burkhoff Cardiovascular Research Foundation and Columbia University

Controversies in Cardiac Pharmacology

Impella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials

The American College of Cardiology/American Heart

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist

The development of cardiogenic shock portends an extremely poor prognosis. Cardiogenic Shock: A Lethal Complication of Acute Myocardial Infarction

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

AllinaHealthSystem 1

Cardiogenic Shock and Initiatives to Reduce Mortality

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting

Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella

Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση. Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Assessing Myocardium at Risk: Applying SYNTAX

The Case for Multivessel Revascularization in Shock

Controversies in Coronary Revascularization. Atlanta CCU April 15, 2016

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood

MANAGEMENT OF CARDIOGENIC SHOCK

SYNTAX score before decision making! Corrado Tamburino, MD, PhD

HOW TO PERFORM LEFT VENTRICULAR ASSISTANCE IN THE CATHLAB. Andreas Baumbach, MD FESC FRCP Bristol Heart Institute University Hospitals Bristol UK

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

R&M Solutions

Section 6 Intra Aortic Balloon Pump

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

DESCRIPTION: Percentage of patients aged 18 years and older undergoing isolated CABG surgery who received an IMA graft

Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI

Transcription:

Rationale for Left Ventricular Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Associate Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional Research Laboratories Boston, MA

2011 PCI Guidelines High Risk PCI I IIa IIb III Elective insertion of an appropriate hemodynamic support device as an adjunct to PCI may be reasonable in carefully selected high risk patients.

Defining Risk during PCI Risk: an exposure to the possibility of loss or injury caused by an action or inaction. To mitigate risk in PCI, ask three questions in advance: 1) Can I achieve angiographic success? 2) Can I do this without causing a complication? 3) Will successful PCI clinically benefit my patient?

Defining Risk during PCI Patient Advanced Age Female Diabetics Prior MI Multivessel disease Renal dysfunction Periph. Vasc. disease Depressed LV function Technical ACC/AHA Classification SCAI Classification Large myocardium at risk (Jeopardy Score) Sole-remaining vessel Unprotected LM Bifurcation lesions Chronic total occlusions Saphenous vein graft Clinical Any ACS (Active Ischemia) Cardiogenic Shock

CABG Risk Calculators 1 Euroscore 2 STS Score 3 Mass-Dac CABG 4 Hannan-CABG 5 Euroscore/Parsonnet 6 CCMRP Coronary Risk Calculators 1 Mayo Clinic 2 Wu-PCI Defining Risk during PCI 3 Mass-Dac PCI 4 SYNTAX Score Risk calculators for the use of circulatory support during PCI do not exist. Existing risk calculators do not account for deranged hemodynamic conditions.

Physiology of High Risk PCI Arterial and Venous Features Govern Myocardial Perfusion 1. Mean arterial pressure 2. Complex coronary anatomy 3. Microvascular obstruction 1. Increased LV-EDP 2. Systemic venous congestion 3. Coronary sinus congestion What is the hemodynamic condition of your patient? Physiol Rev 86: 1263 1308, 2006

Goals of Circulatory Support during PCI A B 1. Stabilize systemic perfusion and improve multi-organ function. 2. Reduce myocardial oxygen demand by limiting LV wall stress. C 3. Augment coronary perfusion. 4. Create a window in time for complete revascularization. - Multi-vessel PCI - Atherectomy/Thrombectomy - Bifurcation PCI

When is Circulatory Support Rational? Patient Advanced Age Female Diabetics Prior MI Multi-vessel disease Renal dysfunction Periph. Vasc. disease Depressed LV function Technical ACC/AHA Classification SCAI Classification Large myocardium at risk (Jeopardy Score) Sole-remaining vessel Unprotected LM Bifurcation lesions Chronic total occlusions Saphenous vein graft Clinical Any ACS (Active Ischemia) Cardiogenic Shock

Anatomic Risk When is Circulatory Support Rational? Revascularization Strategy by Risk Category Surgical Risk Low Medium High Low PCI PCI PCI Medium High CABG or PCI CABG PCI or CABG CABG or PCI Support* & PCI Support* & PCI Protected PCI FDA Indicated Safe & Effective ACC/AHA PCI Guidelines 1,2 * Hemodynamic Instability 1. Levine GN, et al. J Am Coll Cardiol, 2011 Dec 6;58(24):e44-122, 2 Amsterdam EA, et al. Circulation. 2014 Dec 23; 130(25):e344-426

Pressure How is Circulatory Support Supposed to Work? MAP LV EDV LV ESP LV Work LV EDP Maintain Systemic Perfusion Reduced Myocardial O 2 Demand Volume

Left-sided Circulatory Support Options are Expanding Kapur and Esposito. HF Clinic Rev 2014

How does IABP Support Work? MEGA-IABP Hemodynamic Effect: 1. Reduces Systolic Unloading: Pressure 98 75 mmhg 2. Maintains Diastolic MAP Augmentation: by Augmenting 58 Diastolic 122 mmhg Pressure Proximal Aorta Unassisted Systolic Pressure: 98 mmhg Augmented Diastolic Pressure: 122 mmhg Assisted Systolic Pressure: 75 mmhg Unassisted Diastolic Pressure: 58 mmhg

Recent IABP Trials Fail to Show Clinical Benefit Red = Non-Responder Failed to Unload Systolic Pressure by > 10mmHg SHOCK-II ACS CRISP AMI STEMI BCIS-1 PCI 1. No assessment of hemodynamic IABP effect 2. No trials incorporating larger capacity IABPs Arjun Majithia (PGY3) and Kapur et al J Inv Card 2014

Is this tracing reassuring to you? IABP Supported LM PCI LM Balloon Inflation 115 100 90 Not Reassuring 1. Minimal diastolic augmentation prior to LM balloon inflation 2. MAP drops by 25mmHg (115 to 90) 3. Supported MAP driven by Augmented Pressures in Diastole Only

How does Rotodynamic Support Work? plvad (Tandem) Supported LAD PCI Baseline Tandem 6500 rpm 6500 rpm + LAD PTCA 93/57, 69 97/75, 81 73/67, 69 Systemic and coronary perfusion maintained LV EDV LV ESP LV Work LV EDP Reduced Myocardial O 2 Demand

TandemHeart (LA-FA Bypass) pla-fa Bypass

Impella Axial-Flow Catheters Percutaneous: Impella CP (14Fr) LV Asc Ao

A Primary Goal of Circulatory Support is to Reduce LV Pressure and Volume Impella CP Reduces LV Pressure & Volume TandemHeart Primarily Reduces LV Volume James Nilson (PGY8), Michele Esposito (PGY3), and Kapur et al ASAIO 2015

Is this tracing reassuring to you? Pre-Impella CP Pre-LAD PCI Impella CP ON (P6) 2.8 LPM Flow + LAD Occlusion Yes: Reassuring Sustained MAP throughout the cardiac cycle

Next Generation Axial Flow Catheter: Heartmate PHP (St. Jude) 14Fr Sheath 24Fr Impeller Actively Enrolling SHIELD-II : High Risk PCI Trial in USA Randomized 2:1 (HeartMate PHP vs. Impella 2.5)

Does Circulatory Support Work in Elective HR-PCI? (Prophylactic) (Provisional) Prophylactic IABP reduces acute complications, but no change in mortality during PCI in patients with low LVEF. Am Heart J 2003;145:700-7

Does Circulatory Support Work in Elective HR-PCI? Prophylactic, not rescue, IABP improves clinical outcomes during high risk PCI in patients with hemodynamic instability. Am J Cardiol 2006;98:608-12

Does Circulatory Support Work in Elective HR-PCI? BCIS-1 Study HR-PCI Definition: 1. LVEF<30% 2. High Jeopardy Score No 6-month mortality benefit to elective IABP insertion. JAMA. 2010;304(8):867-874

Does Circulatory Support Work in Elective HR-PCI?

Does Circulatory Support Work in Elective HR-PCI? A trend towards benefit with Impella 2.5 over IABP among patients undergoing elective, HR-PCI. Follow up analyses have been informative: 1. Trends towards benefit with ITT analysis favoring Impella 2. Rotational atherectomy is an extreme high risk substrate 3. Learning curve support devices improves outcomes 4. Multi-vessel revascularization may reduce MACCE Circulation 2012

Why the disconnect between hemodynamic effect and clinical outcomes? 1. Patient selection - No hemodynamic criteria in HR-PCI trials. - Underestimating rotational atherectomy 2. Device selection/timing - Poor insight into the mechanics of LV support systems. - Pre-PCI vs Bailout support impacts outcomes. 3. Pursuing patients with extreme high risk. - Salvaging the unsalvageable? 4. Incomplete revascularization / reperfusion

Key Points: High risk PCI is a relative term that is being performed with increasing frequency. There is growing clinical data for the use of circulatory support during high risk PCI. Let the hemodynamics guide your approach: 1. A careful assessment of pre-procedural hemodynamics 2. Anticipated need for intra-procedural support 3. Close monitoring of post-procedural hemodynamic indices during device weaning and removal.

Thank you. nkapur@tuftsmedicalcenter.org